NEW YORK – Cardea Bio said on Thursday that it has raised $7.5 million in the first close of a Series A2 financing round.
The round was led by a partnership of venture capital firms, including Tsingyuan Ventures, Lifespan Investments, and longtime Cardea investor Serra Ventures, as well as Agilent Technologies, Table Mountain Capital, Photon Fund, and Taihill Venture, the company said.